Skip to main content
FDA Updates
Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma
Read More
FDA Updates
Tafinlar plus Mekinist First Tumor Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation
Read More
Meeting Highlights Online Only
ASCO Highlights
PD-1 Inhibition with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer
Read More
Meeting Highlights Online Only
ASCO Highlights
Black Patients with Cancer and COVID-19 More Likely Than White Patients to Have Therapy Disruptions
Read More
Meeting Highlights Online Only
ASCO Highlights
Trastuzumab Deruxtecan a New Standard for Patients with HER2-Low Metastatic Breast Cancer
Read More
Meeting Highlights Online Only
ASCO Highlights
Patients Aged ≥55 Years with Luminal A Breast Cancer Can Safely Avoid Radiation
Read More
Meeting Highlights Online Only
ASCO Highlights
ASCO Highlights Innovation as Key to Equitable Cancer Care
Read More
Online Only
FDA Updates
FDA Issues New Warning for Copiktra About Increased Risks for Serious Side Effects and Mortality
Read More
Online Only
FDA Updates, Monoclonal Antibodies, Bispecific Antibodies
Talquetamab, First-in-Class Bispecific Monoclonal Antibody, Granted Breakthrough Therapy by the FDA for Relapsed or Refractory Multiple Myeloma
Read More
Editorial
Optimal Sequencing of Cancer Treatments an Increasingly Important Question
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Read More
Page 51 of 199
Results 501 - 510 of 1986